Immune Design Shares Down 17% Tues., Down 26% Since Mon. After-Hours High; Co. Announced FDA Feedback Related To Its Phase 3 Trial Design For CMB305; Was Also Downgraded To Market Perform By Wells Fargo
Paul Quintaro